All In Biotech

Drug Trial Radar · NCT00383708

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Phase III, Multicentre, Open Study to Assess the Efficacy and Safety Profiles of the Co-administration of Lanreotide Autogel 120 mg (Administered Via Deep Subcutaneous Injections Every 28 Days) and Pegvisomant 40 to 120 mg Per Week (Administered Via Subcutaneous Route Once or Twice a Week) in Acromegalic Patients Failing to Respond to Lanreotide Autogel 120 mg Alone

Last checked: Nov 20, 2026Latest source record: Sep 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

125

Actual

Start

Oct 2006

Primary completion

Oct 2008

Study completion Oct 2008

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Oct 3, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to assess the efficacy of the co-administration of lanreotide Autogel 120 mg (administered via deep sub-cutaneous injections every 28 days) and pegvisomant (administered at 40 to 120 mg per week via sub-cutaneous injection given once or twice a week) on IGF-1 levels over 28 weeks in acromegalic patients. The primary endpoint will be the percentage of acromegalic patients with normalised (age and sex adjusted) IGF-1 level at the end of the co-treatment period.

Conditions

  • Acromegaly

Interventions

  • lanreotide (Autogel formulation)Drug

    120 mg administered via deep subcutaneous injection every 28 days over 28 weeks.

  • PegvisomantDrug

    Administered at 40 to 120 mg per week via subcutaneous injection once or twice a week over 28 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration PeriodTime frame: V3 (Week 12; Baseline) up to V11 (Week 44)
  2. Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration Period; Summarised by Previous Treatment and by Final Dose of PegvisomantTime frame: V3 (Week 12; Baseline) up to V11 (Week 44)
  3. Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration Period; Summarised by Diabetic Status at BaselineTime frame: V3 (Week 12; Baseline) up to V11 (Week 44)

Locations

24 sites in 10 countries. Site status is shown where the registry gives one.

  • University Hospital, Charles University

    Hradec Králové, Czechia

  • Charles University

    Prague, Czechia

  • Aarhus Kommunehospital

    Aarhus, Denmark

  • Groupe Hospitalier Henri Mondor- Albert Chenevier

    Créteil, France

  • Hôpital Bicêtre

    Le Kremlin-Bicêtre, France

  • Clinique Marc Linquette

    Lille, France

  • Hôpital de la Timone

    Marseille, France

  • CHU de Rangueil

    Toulouse, France

  • Charite Campus Mitte

    Berlin, Germany

  • Klinikum Johann Wolfgang Goethe-Universität

    Frankfurt, Germany

  • Medizinische Klinik Innenstadt

    München, Germany

  • Anticancer Hospital Metaxa Piraeus

    Piraeus, Greece

  • Universitá degli Studi di Milano

    Milan, Italy

  • University Federico II

    Naples, Italy

  • Universitá di Torino

    Torino, Italy

  • Leiden University Medical Center

    Leiden, Netherlands

  • Dept. of Internal Medicine Erasmus MC

    Rotterdam, Netherlands

  • Hospital General de Alicante

    Alicante, Spain

  • Clínica Puerta de Hierro

    Madrid, Spain

  • Hospital Clínico Universitario de Santiago de Compostela

    Santiago de Compostela, Spain

  • Sahlgrenska University Hospital

    Gothenburg, Sweden

  • Uppsala University Hospital

    Uppsala, Sweden

  • Christie Hospital and Holt Radium Institute

    Manchester, United Kingdom

  • Royal Hallamshire Hospital

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.